Payment overview · 2025
General Payments
$241.39
11 reported records · 7 companies
Healthcare provider profile · identity verified
Betsy Negron, MD
Allopathic & Osteopathic Physicians|General Practice · WINTER HAVEN, FL · NPI 1346499449
Verified facts
What the public records show
CMS Open Payments records show Betsy Negron, MD received $241.39 in general payments during 2025 across 11 reported records.
Abbott Laboratories accounted for 28.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Rybelsus.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 143 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $68.20 | 28.2% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $60.08 | 24.9% | 3 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $38.06 | 15.8% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $22.16 | 9.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.92 | 7.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.87 | 7.8% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $15.10 | 6.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $241.39 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $68.20 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $40.79 | 2 | 2025 |
Source payment records
|
|||||
| COLLAGENASE SANTYL Normalized: collagenase santyl |
Drug | Smith+Nephew, Inc. | $38.06 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $22.16 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $20.20 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $18.92 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $18.92 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $18.92 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.87 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.87 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $15.10 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 94 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 143 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 55 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
76 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
94 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
143 | 29 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
55 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
107 | 36 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 777 | 272 |
| Gabapentin | Gabapentin | 567 | 184 |
| Metformin Hcl | Metformin Hcl | 523 | 180 |
| Lisinopril | Lisinopril | 514 | 170 |
| Amlodipine Besylate | Amlodipine Besylate | 498 | 171 |
| Levothyroxine Sodium | Levothyroxine Sodium | 431 | 134 |
| Losartan Potassium | Losartan Potassium | 429 | 151 |
| Omeprazole | Omeprazole | 369 | 128 |
| Pantoprazole Sodium | Pantoprazole Sodium | 357 | 121 |
| Simvastatin | Simvastatin | 329 | 110 |
| Hydrochlorothiazide | Hydrochlorothiazide | 323 | 98 |
| Glipizide | Glipizide | 311 | 92 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 306 | 83 |
| Meloxicam | Meloxicam | 275 | 100 |
| Metoprolol Tartrate | Metoprolol Tartrate | 275 | 97 |
| Furosemide | Furosemide | 227 | 74 |
| Ibuprofen | Ibuprofen | 191 | 79 |
| Alendronate Sodium | Alendronate Sodium | 183 | 55 |
| Metoprolol Succinate | Metoprolol Succinate | 181 | 64 |
| Prednisone | Prednisone | 173 | 74 |
| Famotidine | Famotidine | 171 | 66 |
| Tamsulosin Hcl | Tamsulosin Hcl | 170 | 62 |
| Fluticasone Propionate | Fluticasone Propionate | 168 | 53 |
| Montelukast Sodium | Montelukast Sodium | 168 | 61 |
| Trazodone Hcl | Trazodone Hcl | 163 | 47 |
| Diclofenac Sodium | Diclofenac Sodium | 160 | 39 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 159 | 53 |
| Dicyclomine Hcl | Dicyclomine Hcl | 150 | 49 |
| Pravastatin Sodium | Pravastatin Sodium | 148 | 45 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 144 | 49 |
| Ozempic | Semaglutide | 143 | 29 |
| Baclofen | Baclofen | 138 | 54 |
| Etodolac | Etodolac | 137 | 54 |
| Mirtazapine | Mirtazapine | 135 | 39 |
| Carvedilol | Carvedilol | 124 | 49 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 122 | 76 |
| Mometasone Furoate | Mometasone Furoate | 112 | 54 |
| Cephalexin | Cephalexin | 107 | 79 |
| Eliquis | Apixaban | 107 | 36 |
| Glimepiride | Glimepiride | 106 | 33 |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 106 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 101 | 38 |
| Atenolol | Atenolol | 100 | 34 |
| Clonidine Hcl | Clonidine Hcl | 100 | 34 |
| Clopidogrel | Clopidogrel Bisulfate | 100 | 40 |
| Hydralazine Hcl | Hydralazine Hcl | 97 | 27 |
| Sildenafil Citrate | Sildenafil Citrate | 96 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 95 | 29 |
| Mounjaro | Tirzepatide | 94 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 93 | 29 |
| Oxybutynin Chloride | Oxybutynin Chloride | 91 | 36 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 87 | 35 |
| Tramadol Hcl | Tramadol Hcl | 85 | 28 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 83 | 14 |
| Sertraline Hcl | Sertraline Hcl | 81 | 29 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 80 | 23 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 80 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 78 | 37 |
| Dexamethasone | Dexamethasone | 78 | 20 |
| Jardiance | Empagliflozin | 76 | 22 |
| Sucralfate | Sucralfate | 74 | 31 |
| Clobetasol Propionate | Clobetasol Propionate | 71 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 71 | 20 |
| Lorazepam | Lorazepam | 70 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 68 | 26 |
| Xarelto | Rivaroxaban | 68 | 16 |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 67 | 20 |
| Lovastatin | Lovastatin | 66 | 17 |
| Sumatriptan Succinate | Sumatriptan Succinate | 66 | 19 |
| Azithromycin | Azithromycin | 64 | 42 |
| Ketoconazole | Ketoconazole | 64 | 20 |
| Meclizine Hcl | Meclizine Hcl | 64 | 31 |
| Valsartan | Valsartan | 62 | 18 |
| Clonazepam | Clonazepam | 60 | 23 |
| Celecoxib | Celecoxib | 59 | 27 |
| Linzess | Linaclotide | 59 | 23 |
| Prednisolone Acetate | Prednisolone Acetate | 59 | 31 |
| Allopurinol | Allopurinol | 58 | 16 |
| Valacyclovir | Valacyclovir Hcl | 58 | 18 |
| Rybelsus | Semaglutide | 55 | 16 |
| Albuterol Sulfate | Albuterol Sulfate | 54 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 54 | 16 |
| Bumetanide | Bumetanide | 53 | 14 |
| Glipizide Er | Glipizide | 53 | 18 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 53 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 52 | 18 |
| Alprazolam | Alprazolam | 51 | 15 |
| Metronidazole | Metronidazole | 51 | 25 |
| Quetiapine Fumarate | Quetiapine Fumarate | 51 | 15 |
| Nitroglycerin | Nitroglycerin | 50 | 20 |
| Topiramate | Topiramate | 50 | 13 |
| Buspirone Hcl | Buspirone Hcl | 47 | 16 |
| Enalapril Maleate | Enalapril Maleate | 46 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 46 | 15 |
| Gemfibrozil | Gemfibrozil | 45 | 11 |
| Latanoprost | Latanoprost | 44 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 43 | 14 |
| Ezetimibe | Ezetimibe | 41 | 18 |
| Amitriptyline Hcl | Amitriptyline Hcl | 40 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 39 | 15 |
| Entresto | Sacubitril/Valsartan | 38 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 38 | suppressed |
| Memantine Hcl | Memantine Hcl | 38 | 14 |
| Naproxen | Naproxen | 38 | 17 |
| Acyclovir | Acyclovir | 37 | 11 |
| Levetiracetam | Levetiracetam | 37 | suppressed |
| Fluconazole | Fluconazole | 35 | 16 |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 35 | 15 |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 35 | suppressed |
| Ranolazine Er | Ranolazine | 35 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 34 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 34 | 12 |
| Diclofenac Potassium | Diclofenac Potassium | 33 | 14 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 33 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 32 | 11 |
| Potassium Chloride | Potassium Chloride | 32 | 11 |
| Amoxicillin | Amoxicillin | 31 | 18 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 31 | 12 |
| Januvia | Sitagliptin Phosphate | 31 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 31 | 22 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 31 | 11 |
| Warfarin Sodium | Warfarin Sodium | 31 | 12 |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 30 | 12 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 30 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 29 | 12 |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 29 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 28 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 28 | suppressed |
| Trulicity | Dulaglutide | 28 | suppressed |
| Diazepam | Diazepam | 26 | suppressed |
| Nifedipine Er | Nifedipine | 26 | 13 |
| Ondansetron Odt | Ondansetron | 26 | 16 |
| Calcitriol | Calcitriol | 25 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Temazepam | Temazepam | 25 | suppressed |
| Folic Acid | Folic Acid | 24 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 24 | 18 |
| Ammonium Lactate | Ammonium Lactate | 23 | 19 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Finasteride | Finasteride | 22 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Benzonatate | Benzonatate | 21 | 11 |
| Comfort Ez Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 21 | suppressed |
| Estradiol | Estradiol | 21 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 21 | suppressed |
| Methylprednisolone | Methylprednisolone | 21 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 20 | 12 |
| Metoclopramide Hcl | Metoclopramide Hcl | 20 | 14 |
| Mupirocin | Mupirocin | 20 | suppressed |
| Pregabalin | Pregabalin | 20 | suppressed |
| Premarin | Estrogens, Conjugated | 20 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Carbamazepine | Carbamazepine | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 18 | suppressed |
| Levemir Flexpen | Insulin Detemir | 18 | suppressed |
| Bupropion Xl | Bupropion Hcl | 17 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 17 | suppressed |
| Anastrozole | Anastrozole | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Loperamide | Loperamide Hcl | 16 | 12 |
| Novolog Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 16 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 13 |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 15 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Spironolactone | Spironolactone | 14 | 11 |
| Terconazole | Terconazole | 14 | suppressed |
| Timolol Maleate | Timolol Maleate | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Clotrimazole | Clotrimazole | 13 | suppressed |
| Creon | Lipase/Protease/Amylase | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Trueplus Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 12 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Humalog | Insulin Lispro | 12 | suppressed |
| Indomethacin | Indomethacin | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | suppressed |
| Orphenadrine Citrate Er | Orphenadrine Citrate | 12 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Enulose | Lactulose | 11 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $241.39 · 11 records | Abbott Laboratories | ABRYSVO, COLLAGENASE SANTYL, COMIRNATY, FREESTYLE LIBRE, MOUNJARO, Ozempic, PREVNAR 20, Rybelsus, XIFAXAN, ZEPBOUND, ZORYVE | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error